相关实验视频
Updated: Jan 13, 2026

12:08
Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
19.3K
在急性疾病患者中使用-葡萄糖载体抑制剂2
Fernando G Zampieri1, Melanie Meersch2, Emily See3
1Department of Critical Care Medicine, University of Alberta, Edmonton, Canada.
Current opinion in clinical nutrition and metabolic care
|January 6, 2026
概括
-葡萄糖携带载体-2 抑制剂 (SGLT2i) 对稳定的住院患者是安全的,为和代谢提供了好处. 对于稳定的患者,建议继续治疗,而启动需要进一步研究.
科学领域:
- 心脏病学 心脏病学
- 腎臟病學 (nephrology) 是一種醫學專業.
- 关键护理医学 关键护理医学
背景情况:
- -葡萄糖共传输体-2 抑制剂 (SGLT2i) 越来越多地用于心力衰竭和慢性病.
- 它们在急症护理环境中的应用需要了解它们在严重疾病期间的影响.
研究的目的:
- 审查关于SGLT2i在近急性和重症监护环境中的使用的生理和临床证据.
- 为了解决急性疾病期间是否应该继续或启动SGLT2i.
主要方法:
- 审查最近的生理和临床研究.
- 分析了手术前,心脏和重症监护机构的数据.
主要成果:
- 在急性疾病中,SGLT2i似乎对脏安全.
- 它们可能会促进尿路和脱血,可能会增加不稳定的患者的血管压缩剂需求.
- 代谢和抗炎功效持续存在,没有发现一致的安全问题.
结论:
- 对于稳定住院或重症患者来说,SGLT2i通常是安全的,提供脏和代谢方面的优势.
- 推不建议进行常规的启动,但对于接受营养的稳定性,evolemic患者来说,继续是合理的.
- 需要进一步的研究来优化急性护理使用的时间,剂量和患者选择.
相关概念视频
Glucose Transporters
27.1K
Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
27.1K
Secondary Active Transport
9.3K
One example of how cells use the energy contained in electrochemical gradients is demonstrated by glucose transport into cells. The ion vital to this process is sodium (Na+), which is typically present in higher concentrations extracellularly than in the cytosol. Such a concentration difference is due, in part, to the action of an enzyme "pump" embedded in the cellular membrane that actively expels Na+ from a cell. Importantly, as this pump contributes to the high concentration of...
9.3K
Secondary Active Transport
136.8K
One example of how cells use the energy contained in electrochemical gradients is demonstrated by glucose transport into cells. The ion vital to this process is sodium (Na+), which is typically present in higher concentrations extracellularly than in the cytosol. Such a concentration difference is due, in part, to the action of an enzyme “pump” embedded in the cellular membrane that actively expels Na+ from a cell. Importantly, as this pump contributes to the high concentration of...
136.8K
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
521
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
521
Glucose Absorption Into the Small Intestine
34.9K
Complex carbohydrates consumed cannot be absorbed into the small intestine in their original form. First, they must be hydrolyzed to a monosaccharide form such as glucose or galactose. These monosaccharides are then transported across the intestinal membrane and into the blood via transcellular transport. The intestinal epithelial cells allow the movement of these monosaccharides with a defined 'entry' through membrane transporter proteins present on their apical membrane and...
34.9K
Oral Hypoglycemic Agents: Glinides
593
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
593

